Teva, Viatris win another chance to invalidate J&J’s patent for schizophrenia treatment

Johnson & Johnson only has one last patent covering its long-acting blockbuster schizophrenia drug Invega Sustenna, and now Teva and Viatris have another opportunity to challenge it following a federal circuit panel decision.

J&J’s Janssen unit (now J&J Innovative Medicine) originally sued Teva in 2018 over patent infringement in the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks